Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Osiris Therapeutics (OSIR) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 188,460
  • Shares Outstanding, K 34,450
  • Annual Sales, $ 59,870 K
  • Annual Income, $ -1,790 K
  • 36-Month Beta 0.83
  • Price/Sales N/A
  • Price/Book 2.36

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +18.96%
on 11/08/16
7.39 -28.69%
on 11/11/16
+1.08 (+25.78%)
since 11/07/16
3-Month
4.00 +31.75%
on 11/04/16
7.39 -28.69%
on 11/11/16
-0.42 (-7.38%)
since 09/07/16
52-Week
3.55 +48.45%
on 03/16/16
10.98 -52.00%
on 12/17/15
-4.86 (-47.98%)
since 12/07/15

Most Recent Stories

More News
Osiris Provides Update Regarding NASDAQ Listing Matters

Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company") today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ("NASDAQ").

Peer-reviewed Publication on the use of Grafix(R) in High-Risk Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations Demonstrating Durable Wound Closure

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that a new peer-reviewed manuscript by physician and surgeon Jonathan Smedley, DPM, FACFAS, entitled "Wound Closure in Smoking Peripheral Arterial...

Osiris Therapeutics, Inc. Reports Preliminary 2014 and 2015 Revenue and Anticipated 2016 Revenue

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, today announced its preliminary...

Peer-reviewed Publication on the use of Grafix(R) Prime for Outpatient Management of Complex Wounds with Exposed Bone, Tendon, Muscle, Joint, and Hardware

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics and sports medicine, announced today that a new...

Grafix(R) Cost Comparative Manuscript Reporting Wound Care Cost Reduction is Available Electronically in a Peer-Reviewed Journal

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, announced today that a new...

Osiris to Present Clinical and Scientific Studies at Desert Foot 2016

Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will present...

Net Health and Osiris Therapeutics Announce the Broad Availability of Grafix(R) to Wound Care Patients Due to WoundExpert(R) EMR Integration

Net Health, the leading provider of software solutions for specialized outpatient care, announced today that their partnership with Osiris Therapeutics, Inc. (Nasdaq:OSIR), has made Grafix, a viable cryopreserved...

Osiris to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care (SAWC)

Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, will...

Osiris Therapeutics Announces Appointment of Alberto Avendano, M.D. as Chief Medical Officer

Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has appointed R. Alberto Avendano, M.D., as the Company's Chief Medical Officer.

Osiris Therapeutics to Present at 2016 Cell & Gene Meeting on the Mesa

Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that Alla Danilkovitch, Ph.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

OSIRIS THERAPEUTICS, INC. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel for regenerating bone in orthopedic indications. Prochymal...

See More

Support & Resistance

2nd Resistance Point 5.50
1st Resistance Point 5.39
Last Price 5.27
1st Support Level 5.12
2nd Support Level 4.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.